Research Library

Research Library

Publications

Some of these publications maybe available as reprints. Please contact the NDB if you would like a reprint.

  1. Wolfe F, Michaud K, Li T, Katz RS. EQ-5D and SF-36 Quality of Life Measures in Systemic Lupus Erythematosus: Comparisons with RA, Non-inflammatory Rheumatic Disorders, and Fibromyalgia. J Rheumatol. 2010;37:296-304.
  2. Wolfe F, Michaud K, Li T, Katz BS. Chronic Conditions and Health Problems in Rheumatic Diseases: Comparisons with RA, Non-inflammatory Rheumatic Disorders, Systemic Lupus Erythematosus and Fibromyalgia. J Rheumatol. 2010.
  3. Wolfe F, Michaud K. The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. 2010.
  4. Wolfe F, Marmor MF. Rates and Predictors of Hydroxychloroquine Retinal Toxicity in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus Arthritis Care Res. 2010.
  5. Wolfe F, Clauw D, Fitzcharles MA, Goldenberg D, Katz RS, Mease P, et al. The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity. Arthritis Care Res. 2010.
  6. Wolfe F. New Criteria for fibromyalgia: a twenty year journey. Arthritis Care Res. 2010.
  7. Costenbader KH, Khamashta M, Ruiz-Garcia S, Perez-Rodriguez MT, Petri M, Elliott J, et al. Development and Initial Validation of the Self-Assessed Lupus Damage Index Questionnaire (LDIQ)
  8. Arthritis Care Res. 2010 2010.
  9. Wolfe F, Petri M, Alarcon GS, Goldman J, Chakravarty EF, Katz RS, et al. Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. J Rheumatol. 2009 Jan;36(1):82-8.
  10. Wolfe F, Michaud K. Out of pocket expenses and their burden in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61(11):1563-70.
  11. Wolfe F, Michaud K. Proposed metrics for the determination of rheumatoid arthritis outcome and treatment success and failure. J Rheumatol. 2009 Jan;36(1):27-33.
  12. Wolfe F, Michaud K. Outcome and predictor relationships in fibromyalgia and rheumatoid arthritis: evidence concerning the continuum versus discrete disorder hypothesis. J Rheumatol. 2009 Apr;36(4):831-6.
  13. Wolfe F, Michaud K. Predicting depression in rheumatoid arthritis: the signal importance of pain extent and fatigue, and comorbidity. Arthritis Rheum. 2009 May 15;61(5):667-73.
  14. Wolfe F, Boers M, Felson D, Michaud K, Wells GA. Remission in rheumatoid arthritis: physician and patient perspectives. J Rheumatol. 2009 May;36(5):930-3.
  15. Wolfe F. Fibromyalgia wars. J Rheumatol. 2009 Apr;36(4):671-8.
  16. Wolfe F. Fibromyalgianess. Arthritis Rheum. 2009 Jun 15;61(6):715-6.
  17. Pons-Estel B, Sanchez-Guerrero J, Romero-Diaz J, Inglesias A, Bonfa E, Shinjo SK, et al. Validation of the Spanish, Portuguese and French Versions of the Lupus Damage Index Questionnaire: Data from North and South America, Spain and Portugal. Lupus. 2009;18(12):1033-52.
  18. Bergman MJ, Shahouri SS, Shaver TS, Anderson JD, Weidensaul DN, Busch RE, et al. Is Fatigue an Inflammatory Variable in Rheumatoid Arthritis (RA)? Analyses of Fatigue, Osteoarthritis, and Fibromyalgia. J Rheumatol. 2009;36:2788-94.
  19. Allaire S, Wolfe F, Niu J, LaValley MP, Zhang B, Reisine S. Current risk factors for work disability associated with rheumatoid arthritis: recent data from a US national cohort. Arthritis Rheum. 2009 Mar 15;61(3):321-8.
  20. Wolfe F, Michaud K. Proposed Metrics for the Determination of Rheumatoid Arthritis Outcome and Treatment Success and Failure. J Rheumatol. 2008 Dec 1.
  21. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case-control analysis. Arthritis Rheum. 2008 Sep;58(9):2612-21.
  22. Wolfe F, Michaud K. Prevalence, risk, and risk factors for oral and ocular dryness with particular emphasis on rheumatoid arthritis. J Rheumatol. 2008;35(6):1023-30.
  23. Wolfe F, Michaud K. The challenges of determining RA disease activity and remission in clinical practice. NatClinPractRheumatol. 2008.
  24. Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum. 2008;58(4):939-46.
  25. Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology (Oxford). 2008 Apr;47(4):535-41.
  26. Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O, et al. Cost-Effectiveness of Abatacept in Patients with Moderately to Severely Active Rheumatoid Arthritis and Inadequate Response to Tumor Necrosis Factor-alpha Antagonists. J Rheumatol. 2008.
  27. Simon TA, Smitten AL, Franklin J, Askling J, Lacaille D, Wolfe F, et al. Malignancies in the rheumatoid arthritis abatacept clinical development program: An epidemiological assessment. Ann Rheum Dis. 2008 Dec 3.
  28. Shaver TS, Anderson JD, Weidensaul DN, Shahouri SS, Busch RE, Mikuls TR, et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol. 2008;35(6):1015-22.
  29. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Bingham CO, 3rd, Harris CL, et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum. 2008 Oct;58(10):3183-91.
  30. Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: A nested, case-control study. Arthritis Rheum. 2008;59(8):1090-6.
  31. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II. Arthritis Rheum. 2008;58(1):26-35.
  32. Hoffman HM, Wolfe F, Belomestnov P, Mellis SJ. Cryopyrin-associated periodic syndromes: development of a patient-reported outcomes instrument to assess the pattern and severity of clinical disease activity. Curr Med Res Opin. 2008 Sep;24(9):2531-43.
  33. Cannon GW, Pincus SH, Emkey RD, Denes A, Cohen SA, Wolfe F, et al. Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. 1989. Arthritis Rheum. 2008 Feb;58(2 Suppl):S79-88.
  34. Cannon GW, Pincus SH, Emkey RD, Denes A, Cohen SA, Wolfe F, et al. Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. 2008;58(2 Suppl):S79-S88.
  35. Allaire S, Wolfe F, Niu J, Zhang Y, Zhang B, LaValley M. Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: The jury is still out. Arthritis Rheum. 2008;59(8):1082-9.
  36. Allaire S, Wolfe F, Niu J, LaValley MP. Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US. Arthritis Rheum. 2008;59(4):474-80.
  37. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum. 2008 Oct 15;59(10):1371-7.
  38. Wolfe F, Rasker JJ, Boers M, Wells GA, Michaud K. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum. 2007;57(6):935-42.
  39. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum. 2007;56(9):2886-95.
  40. Wolfe F, Michaud K. Resistance of rheumatoid arthritis patients to changing therapy: Discordance between disease activity and patients' treatment choices. Arthritis Rheum. 2007;56(7):2135-42.
  41. Wolfe F, Michaud K. Assessment of Pain in Rheumatoid Arthritis: Minimal Clinically Significant Difference, Predictors, and the Effect of Anti-Tumor Necrosis Factor Therapy. J Rheumatol. 2007.
  42. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON-YEARS of observation. Arthritis Rheum. 2007;56(5):1433-9.
  43. Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol. 2007;36(3):172-8.
  44. Wolfe F, Allaire S, Michaud K. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol. 2007 Nov;34(11):2211-7.
  45. Wolfe F. The effective use of questionnaires in clinical practice. Arthritis Rheum. 2007;57(5):705-6.
  46. Michaud K, Wolfe F. The development of a rheumatic disease research comorbidity index for use in outpatients patients with RA, OA, SLE and fibromyalgia (FMS). Arthritis and Rheumatism (Suppl). 2007;56(9):S596.
  47. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. BestPractResClinRheumatol. 2007;21(5):885-906.
  48. Marra CA, Marion SA, Guh DP, Najafzadeh M, Wolfe F, Esdaile JM, et al. Not all "quality-adjusted life years" are equal. J ClinEpidemiol. 2007;60(6):616-24.
  49. Lee HS, Irigoyen P, Kern M, Lee A, Batliwalla F, Khalili H, et al. Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis Rheum. 2007;56(6):1745-53.
  50. Garcia EB, Wolfe F. The potentials and challenges of patient registries. Acta ReumatolPort. 2007;32(4):313-5.
  51. Dessein PH, Norton GR, Woodiwiss AJ, Joffe BI, Wolfe F. Influence of Nonclassical Cardiovascular Risk Factors on the Accuracy of Predicting Subclinical Atherosclerosis in Rheumatoid Arthritis. J Rheumatol. 2007;34(5):943-51.
  52. Caplan L, Wolfe F, Russell AS, Michaud K. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol. 2007;34(4):696-705.
  53. Benito-Garcia E, Michaud K, Wolfe F. The Effect of Low-Dose Aspirin on the Decreased Risk of Development of Dyspepsia and Gastrointestinal Ulcers Associated to Cyclooxygenase-2 Selective Inhibitors. J Rheumatol. 2007.
  54. Wolfe F, Rasker JJ. The Symptom Intensity Scale, fibromyalgia, and the meaning of fibromyalgia-like symptoms. J Rheumatol. 2006;33(11):2291-9.
  55. Wolfe F, Michaud K, Strand V. Dr. Wolfe, et al reply. J Rheumatol. 2006;33(2):435.
  56. Wolfe F, Michaud K, Simon T. Can severity be predicted by treatment variables in rheumatoid arthritis administrative data bases? J Rheumatol. 2006;33(10):1952-6.
  57. Wolfe F, Michaud K, Li T. Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales. J Rheumatol. 2006;33(10):1942-51.
  58. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford). 2006;45(11):1370-5.
  59. Wolfe F, Michaud K. Anemia and renal function in patients with rheumatoid arthritis. J Rheumatol. 2006;33(8):1516-22.
  60. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54(2):628-34.
  61. Michaud K, Wolfe F. The association of rheumatoid arthritis and its treatment with sinus disease. J Rheumatol. 2006;33(12):2412-5.
  62. Katz RS, Wolfe F, Michaud K. Fibromyalgia diagnosis: A comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis Rheum. 2006;54(1):169-76.
  63. Goligher EC, Duryea J, Liang MH, Wolfe F, Finckh A. Radiographic joint space width in the fingers of patients with rheumatoid arthritis of less than one year's duration. Arthritis Rheum. 2006;54(5):1440-3.
  64. Garcia EB, Michaud K, Wolfe F. Gastrointestinal prophylactic therapy among patients with arthritis treated by rheumatology specialists. J Rheumatol. 2006;33(4):779-84.
  65. Finckh A, de PP, Katz JN, Neumann G, Lu Y, Wolfe F, et al. Performance of an automated computer-based scoring method to assess joint space narrowing in rheumatoid arthritis: a longitudinal study. Arthritis Rheum. 2006;54(5):1444-50.
  66. Finckh A, Choi HK, Wolfe F. Progression of radiographic joint damage in different eras. Trends towards milder disease in Rheumatoid Arthritis are attributable to improved therapy. AnnRheumDis. 2006.
  67. Dewitt EM, Glick HA, Albert DA, Joffe MM, Wolfe F. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior. ArchInternMed. 2006;166(1):57-63.
  68. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. NEnglJ Med. 2006;354(8):795-808.
  69. Allaire S, Wolfe F, Niu J, Baker N, Michaud K, LaValley M. Extent of occupational hand use among persons with rheumatoid arthritis. Arthritis Rheum. 2006;55(2):294-9.
  70. Wolfe F, Michaud K, Strand V. Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol. 2005;32(4):583-9.
  71. Wolfe F, Michaud K, Pincus T, Pangan AL, Kent j. Usefulness Of A Visual Analog Function Scale In Ra Clinical Trials: Increased Sensitivity Compared With Conventional Measures. ArthritisRheum. 2005;50.
  72. Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum. 2005;52(12):3873-9.
  73. Wolfe F, Michaud K, Pincus T. A Composite Disease Activity Scale for Clinical Practice, Observational Studies and Clinical Trials: The Patient Activity Scale (PAS/PAS-II). JRheumatol. 2005;32(12):2410-5.
  74. Wolfe F, Michaud K, Pincus T. Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis. J Rheumatol. 2005;32(7):1261-6.
  75. Wolfe F, Michaud K, Choi HK, Williams R. Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol. 2005;32(10):1875-83.
  76. Wolfe F, Michaud K. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness. Rheumatology (Oxford). 2005;44 Suppl 4:iv18-iv22.
  77. Wolfe F, Michaud K. A brief introduction to the National Data Bank for Rheumatic Diseases. Clin ExpRheumatol. 2005;23(5):S168-S71.
  78. Wolfe F, Katz RS, Michaud K. Jaw Pain: Its Prevalence and Meaning in Patients with Rheumatoid Arthritis, Osteoarthritis, and Fibromyalgia. J Rheumatol. 2005;32(12):2421-8.
  79. Wolfe F. Why the HAQ-II can be an effective substitute for the HAQ. ClinExpRheumatol. 2005;23(5 Suppl 39):S29-S30.
  80. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol. 2005;32(10):2016-24.
  81. Ward RJ, Chris Buckland-Wright J, Wolfe F. Relationships between tibial rim alignment and joint space width measurement reproducibility in non-fluoroscopic radiographs of osteoarthritic knees. OsteoarthritisCartilage. 2005.
  82. Walker N, Michaud K, Wolfe F. Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients. J Rheumatol. 2005;32(6):1006-12.
  83. Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, et al. Replication of Putative Candidate-Gene Associations with Rheumatoid Arthritis in >4,000 Samples from North America and Sweden: Association of Susceptibility with PTPN22, CTLA4, and PADI4. AmJ HumGenet. 2005;77(6):1044-60.
  84. Pincus T, Yazici Y, Yazici H, Kavanaugh AF, Kremer JM, Wolfe F. Radiographic benefit without clinical improvement in infliximab-treated patients with rheumatoid arthritis: Comment on the article by Smolen et al. Arthritis Rheum. 2005;52(12):4044-5.
  85. Pincus T, Wolfe F. Patient questionnaires for clinical research and improved standard patient care: is it better to have 80% of the information in 100% of patients or 100% of the information in 5% of patients? J Rheumatol. 2005;32(4):575-7.
  86. Mazzuca SA, Brandt KD, Schauwecker DS, Katz BP, Meyer JM, Lane KA, et al. Severity of joint pain and kellgren-lawrence grade at baseline are better predictors of joint space narrowing than bone scintigraphy in obese women with knee osteoarthritis. J Rheumatol. 2005;32(8):1540-6.
  87. Lee AT, Li W, Liew A, Bombardier C, Weisman M, Massarotti EM, et al. The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status. Genes Immun. 2005;6(2):129-33.
  88. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005;32(11):2130-5.
  89. Caplan L, Russell AS, Wolfe F. Steroids for rheumatoid arthritis: the honeymoon revisited (once again). J Rheumatol. 2005;32(10):1863-5.
  90. Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum. 2005;52(7):2015-25.
  91. Ang DC, Choi H, Kroenke K, Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol. 2005;32(6):1013-9.
  92. Allaire S, Wolfe F, Niu J, LaValley M, Michaud K. Work disability and its economic effect on 55-64-year-old adults with rheumatoid arthritis. Arthritis Rheum. 2005;53(4):603-8.
  93. Wolfe F, Zhao S, Pettitt D. Blood Pressure Destabilization and Edema Among 8538 Users of Celecoxib, Rofecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs (NSAID) and Nonusers of NSAID Receiving Ordinary Clinical Care. JRheumatol. 2004;31(6):1143-51.
  94. Wolfe F, Michaud K, Pincus T. Development and validation of the health assessment questionnaire II: a revised version of the health assessment questionnaire. Arthritis Rheum. 2004;50(10):3296-305.
  95. Wolfe F, Michaud K, Pincus T. Do rheumatology cost-effectiveness analyses make sense? Rheumatology(Oxford). 2004;43(1):4-6.
  96. Wolfe F, Michaud K, Kahler K, Omar M. The Short Arthritis Assessment Scale: a brief assessment questionnaire for rapid evaluation of arthritis severity in research and clinical practice. JRheumatol. 2004;31(12):2472-9.
  97. Wolfe F, Michaud K, Dewitt EM. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. AnnRheumDis. 2004;63 Suppl 2:ii13-ii7.
  98. Wolfe F, Michaud K, Burke TA, Zhao SZ. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. JRheumatol. 2004;31(2):355-8.
  99. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004;50(2):372-9.
  100. Wolfe F, Michaud K. Data collection, maintenance, and analysis for rheumatic disease research. RheumDisClinNorth Am. 2004;30(4):753-68.
  101. Wolfe F, Michaud K. Prednisone but not biologics or DMARDs is associated with increased risk of myocardial infarction in persons with RA. AnnRheumDis. 2004;63:69.
  102. Wolfe F, Michaud K. Rates and risk factors for herpes zoster in patients with rheumatoid arthritis. AnnRheumDis. 2004;63:103.
  103. Wolfe F, Michaud K. Corticosteroids increase the risk of diabetes mellitus in RA and contribute to the risk of myocardial infarction and heart failure. AnnRheumDis. 2004;63:379.
  104. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50(6):1740-51.
  105. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. AmJMed. 2004;116(5):305-11.
  106. Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. JRheumatol. 2004;31(4):695-700.
  107. Wolfe F, Caplan L, Michaud K. Measuring the efficacy and effectiveness of rheumatoid arthritis therapy: time to change our thinking and adopt a new model. JRheumatol. 2004;31(12):2317-9.
  108. Wolfe F. Rheumatology grand rounds at rush: patient self-report data are key to better patient care. J ClinRheumatol. 2004;10(6):347-9.
  109. Wolfe F. Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. JRheumatol. 2004;31(10):1896-902.
  110. Wolfe F. From the outside of Plato's cave. Rheumatology(Oxford). 2004;43(1):112-3.
  111. Wolfe F. A short history of data banking in the United States from 1974 to 2003. JRheumatolSuppl. 2004;69:41-5.
  112. Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. JRheumatol. 2004;31(8):1538-45.
  113. Sharp JT, Wolfe F, Lassere M, Boers M, van der HD, Larsen A, et al. Variability of precision in scoring radiographic abnormalities in rheumatoid arthritis by experienced readers. JRheumatol. 2004;31(6):1062-72.
  114. Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Wolfe F. Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently. J Rheumatol. 2004;31(8):1621-9.
  115. Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. AnnRheumDis. 2004;63(8):931-9.
  116. Mazzuca SA, Brandt KD, Katz BP, Lane KA, Bradley JD, Heck LW, et al. Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoarthritis drug. Arthritis Rheum. 2004;51(6):933-40.
  117. Fewell z, Hernan MA, Wolfe F, Tilling H, Choi HK, Sterne AC. Controlling for time-dependent confounding using marginal structural models. Stata Journal. 2004;4(4):402-20.
  118. Wolfe F, Pincus T, Thompson AK, Doyle J. The assessment of rheumatoid arthritis and the acceptability of self-report questionnaires in clinical practice. Arthritis Rheum. 2003;49(1):59-63.
  119. Wolfe F, Michaud K, Stephenson B, Doyle J. Toward a Definition and Method of Assessment of Treatment Failure and Treatment Effectiveness: The Case of Leflunomide versus Methotrexate. JRheumatol. 2003;30(8):1725-32.
  120. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum. 2003;48(6):1530-42.
  121. Wolfe F, Michaud K, Choi HK, Williams R. Annual and lifetime productivity costs and income losses in Persons with Rheumatoid Arthritis. Arthritis and Rheumatism (Suppl). 2003;48:S243.
  122. Wolfe F, Fries JF. Rate of death due to leukemia/lymphoma in patients with rheumatoid arthritis. Arthritis Rheum. 2003;48(9):2694-5.
  123. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. JRheumatol. 2003;30(1):36-40.
  124. Wolfe F, Burke TA, Pettitt D. Do gastroprotective drugs prevent NSAID toxicity? Reply. JRheumatol. 2003;30(1):203-.
  125. Wolfe F. Stop using the American College of Rheumatology criteria in the clinic. JRheumatol. 2003;30(8):1671-2.
  126. Wolfe F. Pain extent and diagnosis: development and validation of the regional pain scale in 12,799 patients with rheumatic disease. JRheumatol. 2003;30(2):369-78.
  127. Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum. 2003;48(3):625-30.
  128. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum. 2003 Oct;48(10):2750-62.
  129. Wolfe F, Pincus T, Tennant A. HAQ-II: Application of modern item response theory to the design of an improved HAQ questionnaire. AnnRheumDis. 2002;61:190.
  130. Wolfe F, Michaud K. Toward an acceptable definition of DMARD failure and abnormal health status in RA. Arthritis and Rheumatism (Suppl). 2002;46(9):S865.
  131. Wolfe F, Lane NE, Buckland-Wright C. Radiographic Methods in Knee Osteoarthritis: A Further Comparison of Semiflexed (MTP), Schuss-Tunnel, and Weight-Bearing Anteroposterior Views for Joint Space Narrowing and Osteophytes. JRheumatol. 2002;29(12):2597-601.
  132. Wolfe F, Lane NE. The longterm outcome of osteoarthritis: rates and predictors of joint space narrowing in symptomatic patients with knee osteoarthritis. JRheumatol. 2002;29(1):139-46.
  133. Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. JRheumatol. 2002;29(5):1015-22.
  134. Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. JRheumatol. 2002;29(3):467-73.
  135. Wolfe F. The determination and measurement of functional disability in rheumatoid arthritis. Arthritis Res. 2002;4 Suppl 2:S11-S5.
  136. Wolfe F. The psychometrics of functional status questionnaires: room for improvement. JRheumatol. 2002;29(5):865-8.
  137. Wolfe F. Hypertension among patients with rheumatoid and osteoarthritis participating in the National Data Bank for Rheumatic Diseases. JRheumatol. 2002.
  138. Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology(Oxford). 2002;41(12):1346-56.
  139. Hurst S, Kallan MJ, Wolfe FJ, Fries JF, Albert DA. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects. JRheumatol. 2002;29(8):1639-45.
  140. Fries JF, Wolfe F, Apple R, Erlich H, Bugawan T, Holmes T, et al. HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias. Arthritis Rheum. 2002;46(9):2320-9.
  141. Ethgen O, Kahler KH, Kong SX, Reginster JY, Wolfe F. The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis. JRheumatol. 2002;29(6):1147-55.
  142. Duryea J, Zaim S, Wolfe F. Neural network based automated algorithm to identify joint locations on hand/wrist radiographs for arthritis assessments. MedPhys. 2002;29(3):403-11.
  143. Choi HK, Michaud K, Wolfe F. Utility measures in rheumatic diseases. Arthritis and Rheumatism (Suppl). 2002;46(9).
  144. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate therapy and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173-7.
  145. Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun. 2002;3(3):170-6.
  146. Wolfe F, Strand V. Radiography of rheumatoid arthritis in the time of increasing drug effectiveness795. CurrRheumatolRep. 2001;3(1):46-52.
  147. Wolfe F, Rehman Q, Lane NE, Kremer J. Starting a disease modifying antirheumatic drug or a biologic agent in rheumatoid arthritis: standards of practice for RA treatment1143. JRheumatol. 2001;28(7):1704-11.
  148. Wolfe F, Pincus T, O'Dell J. Evaluation and documentation of rheumatoid arthritis disease status in the clinic: which variables best predict change in therapy. JRheumatol. 2001;28(7):1712-7.
  149. Wolfe F, Pincus T, Fries JF. Usefulness of the HAQ in the clinic. AnnRheumDis. 2001;60(8):811.
  150. Wolfe F, Pincus T. The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness. JRheumatol. 2001;28(8):1817-24.
  151. Wolfe F, O'Dell JR, Kavanaugh A, Wilske K, Pincus T. Evaluating severity and status in rheumatoid arthritis1328. JRheumatol. 2001;28(6):1453-62.
  152. Wolfe F, Flowers N, Anderson J, Urbansky K. Tuberculosis rates are not increased in rheumatoid arthritis (RA). Arthritis and Rheumatism (Suppl). 2001;44(9):S105-S-.
  153. Wolfe F, Cush JJ, O'Dell JR, Kavanaugh A, Kremer JM, Lane NE, et al. Consensus recommendations for the assessment and treatment of rheumatoid arthritis1330. JRheumatol. 2001;28(6):1423-30.
  154. Wolfe F, Choi HK. Benchmarking and the percentile assessment of RA: adding a new dimension to rheumatic disease measurement. AnnRheumDis. 2001;60(11):994-5.
  155. Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation. JRheumatol. 2001;28(5):982-9.
  156. Wolfe CV. Disability evaluation of fibromyalgia. Phys Med Rehabil Clin N Am. 2001 Aug;12(3):709-18.
  157. Pincus T, Wolfe F, Strand V, Kavanaugh A, Crawford B, Felson D. Patient questionnaire data discriminate between drug versus placebo as effectively as the ACR20 in a clinical trial of patients with rheumatoid arthritis (RA). Arthritis and Rheumatism (Suppl). 2001;43(9):S288.
  158. Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum. 2001;44(6):1234-6.
  159. Pincus T, Koch GG, Sokka T, Lefkowith J, Wolfe F, Jordan JM, et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee1214. Arthritis Rheum. 2001;44(7):1587-98.
  160. Hawley DJ, Wolfe F, Lue FA, Moldofsky H. Seasonal symptom severity in patients with rheumatic diseases: a study of 1,424 patients. J Rheumatol. 2001 Aug;28(8):1900-9.
  161. Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum. 2000;43(2):378-85.
  162. Wolfe F, van der Heijde DM, Larsen A. Assessing radiographic status of rheumatoid arthritis: introduction of a short erosion scale. JRheumatol. 2000;27(9):2090-9.
  163. Wolfe F, Skevington SM. Measuring the epidemiology of distress: The rheumatology distress index. JRheumatol. 2000;27(8):2000-9.
  164. Wolfe F, Pincus T. The rheumatoid arthritis percentile activity score (PAS): methods and validation. Arthritis and Rheumatism (Suppl). 2000;43(9):S151.
  165. Wolfe F, Kong SX, Watson DJ. Gastrointestinal symptoms and health related quality of life in patients with arthritis. JRheumatol. 2000;27(6):1373-8.
  166. Wolfe F, Hawley DJ, Goldenberg DL, Russell IJ, Buskila D, Neumann L. The assessment of functional impairment in fibromyalgia (FM): Rasch analyses of 5 functional scales and the development of the FM Health Assessment Questionnaire. JRheumatol. 2000;27(8):1989-99.
  167. Wolfe F, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: A prospective 13 year study of 2131 patients. JRheumatol. 2000;27(7):1668-73.
  168. Wolfe F. Management of fibromyalgia. Ann Intern Med. 2000 Jun 20;132(12):1004; author reply 5.
  169. Wolfe F. For example is not evidence: fibromyalgia and the law. J Rheumatol. 2000 May;27(5):1115-6.
  170. Wolfe F. The importance of gastrointestinal (GI) symptom severity in rheumatoid and osteoarthritis: symptom rates and risk for GI hospitalization. J Rheumatol. 2000;27(7):1661-7.
  171. Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum. 2000;43(12):2751-61.
  172. Wolfe F. Sayin' ''Stand and deliver, for you are a bold deceiver'': Faking Fibromyalgia. JRheumatol. 2000;27(11):2534-5.
  173. Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis [see comments]. JRheumatol. 2000;27(3):630-7.
  174. Pincus T, Wolfe F. An infrastructure of patient questionnaires at each rheumatology visit: improving efficiency and documenting care. J Rheumatol. 2000;27(12):2727-30.
  175. Albert DA, Aksentijevich S, Hurst S, Fries JF, Wolfe F. Modeling therapeutic strategies in rheumatoid arthritis: Use of decision analysis and Markov models. JRheumatol. 2000;27(3):644-52.
  176. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs [see comments] [published erratum appears in N Engl J Med 1999 Aug 12;341(7):548]. New England Journal of Medicine. 1999;340(24):1888-99.
  177. Wolfe F, Pincus T. Current comment - Listening to the patient - A practical guide to self-report questionnaires in clinical care. Arthritis Rheum. 1999;42(9):1797-808.
  178. Wolfe F, Lassere M, van der HD, Stucki G, Suarez-Almazor M, Pincus T, et al. Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology45. JRheumatol. 1999;26(2):484-9.
  179. Wolfe F, Kong SX. Rasch analysis of the Western Ontario MacMaster questionnaire (WOMAC) in 2205 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Ann Rheum Dis. 1999;58(9):563-8.
  180. Wolfe F, Hawley DJ, Pincus T. Standard values for self-report questionnaires: assessments in 20,574 rheumatic disease patients. Arthritis and Rheumatism (Suppl). 1999;42:S75-S.
  181. Wolfe F, Hawley DJ, Pincus T. Disease modifying antirheumatic drugs (DMARD) and DMARD combination use by 3604 patients of 303 US rheumatologists. Arthritis and Rheumatism (Suppl). 1999;42:S379.
  182. Wolfe F, Hawley DJ, Anderson JA. Inflammation as measured by the esr predicts cardiovascular mortality across all rheumatic disorders: a 25-year prospective study 0f 5,822 patients. Arthritis and Rheumatism (Suppl). 1999;42(9):S299.
  183. Wolfe F, Hawley DJ. Evidence of disordered symptom appraisal in fibromyalgia: increased rates of reported comorbidity and comorbidity severity. Clin Exp Rheumatol. 1999 May-Jun;17(3):297-303.
  184. Wolfe F, Anderson J. Silicone filled breast implants and the risk of fibromyalgia and rheumatoid arthritis. JRheumatol. 1999;26(9):2025-8.
  185. Wolfe F. Psychological distress and rheumatic disease39. ScandJRheumatol. 1999;28(3):131-6.
  186. Wolfe F. Determinants of WOMAC function, pain and stiffness scores: evidence for the role of low back pain, symptom counts, fatigue and depression in osteoarthritis, rheumatoid arthritis and fibromyalgia. Rheumatology (Oxford). 1999;38(4):355-61.
  187. Wolfe F. The burden of rheumatoid arthritis. AmJ ManagCare. 1999;5(14):S852-S9.
  188. Wolfe F. Critical issues in longitudinal and observational studies: Purpose, short versus long term, selection of study instruments, methods, outcomes, and biases. JRheumatol. 1999;26(2):469-72.
  189. Wolfe F. "Silicone Related Symptoms" Are Common In Patients with Fibromyalgia:No Evidence for A New Disease. JRheumatol. 1999;26(5):1172-5.
  190. Wolfe EW, Chiu CW. Measuring pretest-posttest change with a Rasch Rating Scale Model. J OutcomeMeas. 1999;3(2):134-61.
  191. Wolfe EW, Chiu CW. Measuring change across multiple occasions using the Rasch Rating Scale Model. J OutcomeMeas. 1999;3(4):360-81.
  192. Smolen JS, Strand V, Cardiel M, Edworthy S, Furst D, Gladman D, et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: Consensus on a preliminary core set of outcome domains. JRheumatol. 1999;26(2):504-7.
  193. Pincus T, Swearingen C, Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum. 1999 Oct;42(10):2220-30.
  194. Maini RN, Wolfe F. Workshop summary: health outcomes and health economic issues surrounding the use of biological therapies in patients with rheumatoid arthritis. Rheumatology(Oxford). 1999;38 Suppl 2:48-9.
  195. Kavanaugh AF, Wolfe F, Ward M. New treatments for rheumatoid arthritis: A managed care perspective - Questions and answer session. AmJ ManagCare. 1999;5(14):S866-S9.
  196. Kavanaugh AF, Wolfe F, Auslander M, Bresloff T, Clark DL, Hillman D, et al. Roundtable II: Cost concerns for rheumatoid arthritis treatment. AmJ ManagCare. 1999;5(14):S880-S8.
  197. Hawley DJ, Wolfe F, Pincus T. Use of combination therapy in the routine care of patients with rheumatoid arthritis: Physician and patient surveys. ClinExpRheumatol. 1999;17(6):S78-S82.
  198. Flowers N, Wolfe F. What do rheumatologists do in their practices? Arthritis and Rheumatism (Suppl). 1999;41(9):S337.
  199. Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group491. JRheumatol. 1999;26(11):2438-47.
  200. Buckland-Wright JC, Wolfe F, Ward RJ, Flowers N, Hayne C. Substantial superiority of semiflexed (MTP) views in knee osteoarthritis: A comparative radiographic study, without fluoroscopy, of standing extended, semiflexed (MTP), and schuss views. JRheumatol. 1999;26(12):2664-74.
  201. Aronoff GM, Markowitz M, Dorto AJ, Ranavaya MI, Talmage JB, Wolfe F, et al. AADEP Position Paper - Fibromyalgia: impairment and disability issues. American Academy of Disability Examining Physicians. 1999;8(3 - Special Pull out section):1-10.
  202. Wolfe FA. The causes of fibromyalgia. JcrJ ClinRheumatol. 1998;4(6):299-300.
  203. Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: A 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum. 1998;41(6):1072-82.
  204. Wolfe F, Winfield JB. Fibromyalgia Consensus Report: A few more comments. JcrJ ClinRheumatol. 1998;4(3):118-9.
  205. Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: A 19-year study of radiographic progression. Arthritis Rheum. 1998;41(9):1571-82.
  206. Wolfe F, Neumann L, Buskila D. Altered nociception, but not fibromyalgia, after cervical spine injury: Comment on the article by Buskila et al - Reply. Arthritis Rheum. 1998 -32676;41(1):183-4.
  207. Wolfe F, Hawley DJ, Pincus T. Methotrexate alters the course of rheumatoid arthritis (RA). Increased survival of methotrexate treated RA patients: a 25-years study of 1,842 patients. Arthritis Rheum. 1998;41(9):S188.
  208. Wolfe F, Hawley DJ. The long-term outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients. JRheumatol. 1998;25(11):2108-17.
  209. Wolfe F, Hawley DJ. Psychosocial factors and the fibromyalgia syndrome. ZRheumatol. 1998;57:88-91.
  210. Wolfe F, Flowers N, Anderson J. The National Rheumatic Disease Data Bank: case mix and severity characteristics of patients in rheumatological practice. Arthritis and Rheumatism (Suppl). 1998;41(9):S132.
  211. Wolfe F, Albert DA, Pincus T. A survey of United States rheumatologists concerning effectiveness of disease-modifying antirheumatic drugs and prednisone in the treatment of rheumatoid arthritis. ArthritCare Res. 1998;11(5):375-81.
  212. Wolfe F. Inflammatory activity, but not methotrexate or prednisone use predicts non_Hodgkin's lymphoma in rheumatoid arthritis. Arthritis and Rheumatism (Suppl). 1998;41:S188.
  213. Wolfe F. What use are fibromyalgia control points? Dr. Wolfe replies. JRheumatol. 1998;25(12):2476.
  214. Wolfe F. What use are fibromyalgia control points? JRheumatol. 1998;25(3):546-50.
  215. Wolfe F. A comparison of IgM rheumatoid factor by nephelometry and latex methods: Clinical and laboratory significance. ArthritCare Res. 1998;11(2):89-93.
  216. Wolfe F. Fibromyalgia in a grand bio-psycho-social model - Reply. JRheumatol. 1998;25(5):1029-30.
  217. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41(5):778-99.